UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share ...

ResMed knows a thing or two about headbands: The company actually specializes in respiratory devices (CPAP) for sleep apnoea ... They have extensive knowledge of products that are worn on the ...

The global anti-snoring devices market, valued at US$ 0.83 billion in 2023, is forecasted to grow at a robust CAGR of 9.8%, reaching US$ 0.91 ...

Analyst Lyanne Harrison of Bank of America Securities reiterated a Buy rating on Resmed (RMD – Research Report), retaining the price target of ...

ResMed on Tuesday announced that it has launched AirSense 11 in India. According to the company’s statement, it is the next-generation Continuous Positive Airway Pressure (CPAP) device designed ...

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

Analysts at Catapult Wealth are positive on sleep treatment company ResMed and think it could be an ASX 200 share to buy. Catapult Wealth's analysts have been pleased with ResMed's performance in ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Trump’s executive orders included overhauls to U.S. trade policy and declaring a national emergency at the southern border.

First off the block is ResMed. It is in the sleep apnoea treatment business. Sleep apnoea is treated using continuous positive airway pressure (CPAP) machines. This is ResMed's niche. After ...

The "Sleep Apnea Devices Market Forecast Report by Types, Therapeutic Devices, Diagnostic Devices, End User, Country and ...